Paromomycin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 19.12.2024

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

An orally administered aminoglycoside antibiotic from Streptomyces rimosus forma paromycinus that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. It is no longer used as an antibiotic, but was approved in India in 2007 as an effective, well-tolerated and affordable treatment for visceral leishmaniasis (VL) at a dose of 11 mg/kg (base) for 21 days.

IndicationThis section has been translated automatically.

Paromomycin in combination with sodium stibogluconate has been shown to be effective in African and Indian VL and improves survival in African visceral leishmaniasis (VL). To prevent the emergence of drug-resistant leishmaniasis in areas with anthroponotic transmission (India and Africa), paromomycin should be used as part of combination therapy for VL (Davidson RN et al. 2009).

Dosage and method of useThis section has been translated automatically.

Systemic: 25-30 mg/kg bw/day p.o. in 3 ED over 5-10 days.

Topical: Apply 10-20% in ointments or creams 1-2 times/day under occlusion to the affected skin areas.

Undesirable effectsThis section has been translated automatically.

Oto- and nephrotoxicity.

PreparationsThis section has been translated automatically.

Humatin; Leshcutan (available through the international pharmacy, registered in Israel)

Note(s)This section has been translated automatically.

Remember! In ointment form effective against cutaneous leishmaniasis.

LiteratureThis section has been translated automatically.

  1. Davidson RN et al (2009) Paromomycin. Trans R Soc Trop Med Hyg 103:653-660.

  2. Fernandez-Flores A et al. (2015) Morphological and immunohistochemical clues for the diagnosis of cutaneous leishmaniasis and the interpretation of CD1a status. J Am Acad Dermatol doi: 10.1016/j.jaad.2015.09.038
  3. Fischer T et al. (2024)Treatment of mucocutaneous leishmaniasis- a systematic review. JDDG 22:763-774
  4. Handler MZ et al. (2015) Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.J Am Acad Dermatol. 2015 Dec;73(6):911-26; 927-8.

Authors

Last updated on: 19.12.2024